3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
5
Recurrence
3
Neoplasm Metastasis
3
Melanoma
3
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Cutaneous Squamous Cell Carcinoma
2
Carcinoma, Basal Cell
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Neoplasms
1
Multiple Myeloma
1
Lymphoma
1
Head and Neck Neoplasms
1
Glioma
1
Glioblastoma
1
Diffuse Intrinsic Pontine Glioma
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Merkel Cell
1
Breast Neoplasms
1
Advanced Non-Small Cell Lung Carcinoma
1
Adenocarcinoma
1
Interventions
vandetanib
7
Sorafenib
6
Magnetic Resonance Spectroscopy
6
lenvatinib
5
cabozantinib
5
Sunitinib
4
Iodine-131
4
selpercatinib
3
AZD 6244
3
trametinib
2
tipifarnib
2
durvalumab
2
dabrafenib
2
alectinib
2
Triiodothyronine
2
Thyroxine
2
Thyrotropin Alfa
2
Paclitaxel
2
Nivolumab
2
Ipilimumab
2
Fluorodeoxyglucose F18
2
Everolimus
2
Bortezomib
2
Axitinib
2
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
2
tremelimumab
1
temsirolimus
1
tanespimycin
1
sapanisertib
1
romidepsin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Thyroid Neoplasms
×
cemiplimab
×
Clear all
No trials found.